retatrutide triple agonist obesity phase 2 trial Eli Lilly just announced striking 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% retatrutide triple agonist glp-1 gip

According to the results of a systematic review, the prevalence rate of depression is three times higher in patients with type 1 diabetes mellitus (T1DM) and more than two times higher in patients with T2DM [16]

It has served patients well for decades and remains a viable option in certain clinical scenarios

Significance of the review GLP-1 RAs have shown significant effectiveness so far in a variety of metabolic disorders, and there is increasing interest in their potential effects on CVDs and NDs

There are no current recommendations by ICMR, but studies have shown beneficial effects using the dose mentioned below

Related Reading Temporary Glp 1 Provider While Prior Authorization Pending Plexusdx Glp 1S Does My Dna Test Show If I M At Risk For Alzheimer S Or Dementia Can A Dna Test Reveal If I Will Benefit From Glp 1 Medications Pricing and availability current as of June 2026